Brand Name, Dosage Format and Strength
Cardepine 2 mg/2 mL Solution for Injection
Therapeutic Category
Cardiovascular and Hematopoietic System
Class
Angiotensin-Converting Enzyme Inhibitor, Angiotensin-Converting Enzyme Inhibitor, Diuretic, Angiotensin-II Receptor Blocker, Angiotensin-II Receptor Blocker, Diuretic, 3-Ketoacyl Coenzyme A Thiolase (3-KAT) Inhibitor, Nitrates Salicylate, Antiplatelet, Peripheral Vasodilator, Beta-Andrenoceptor Blocker, Calcium Channel Blocker, Direct-acting Inotropic Agent, Diuretic, Angiotensin-Converting Enzyme Inhibitor, Diuretic, Angiotensin-II Receptor Blocker, Diuretic, Fibric Acid Derivative, HMG-CoA Reductase Inhibitor, Recombinant Human Erythropoietin, Hemostatics
OVERDOSE AND TREATMENT
Studies in laboratory animals showed that lethal nicardipine overdose may cause systemic hypotension, bradycardia (following initial tachycardia) and progressive AV conduction block. Reversible hepatic function abnormalities and sporadic focal hepatic necrosis were also noted in test animals.
Standard measures including monitoring of cardiac and respiratory functions should be implemented as part of the management of nicardipine overdosage. Place the patient in supine position with legs elevated to avoid cerebral anoxia. If this is not adequate, increase plasma volume by infusion of glucose, saline or dextran. Frequent BP monitoring is essential. In case of accompanying bradycardia, administer atropine IV. Pressor therapy and intravenous calcium gluconate should be reserved for patients with hypotension unresponsive to IV fluids.